H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Exploring Men s Prostate Cancer Genetic Risk Perceptions

Active, not recruiting

Conditions: Prostate Cancer

First Posted Date: 2025-01-09

Last Posted Date: 2025-01-09

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 100

Registration Number: NCT06764992

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

Phase 2

Recruiting

Conditions: Large B-cell Lymphoma

Interventions: Drug: Tafasitamab
Drug: Lenalidomide

First Posted Date: 2025-01-06

Last Posted Date: 2025-01-07

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 28

Registration Number: NCT06760156

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Phase 2

Not yet recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed
Drug: Pembrolizumab
Drug: Abraxane
Drug: Paclitaxel

First Posted Date: 2024-12-20

Last Posted Date: 2025-01-10

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 24

Registration Number: NCT06745882

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening

Not Applicable

Recruiting

Conditions: Colorectal Cancer Screening
Hepatitis C Virus

First Posted Date: 2024-12-20

Last Posted Date: 2024-12-20

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 350

Registration Number: NCT06745895

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Phase 2

Recruiting

Conditions: Metastatic Castration Sensitive Prostate Cancer

Interventions: Drug: Luteinizing Hormone-Releasing Hormone (LHRH) analog
Drug: Androgen Receptor Signal Inhibitor (ARSI)
Drug: Docetaxel

First Posted Date: 2024-12-16

Last Posted Date: 2024-12-30

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 25

Registration Number: NCT06734130

Locations: 🇺🇸
Moffitt Caner Center, Tampa, Florida, United States

Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center

Not Applicable

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma
Intraductal Papillary Mucinous Neoplasm

First Posted Date: 2024-12-02

Last Posted Date: 2024-12-02

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 24

Registration Number: NCT06712797

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Digoxin Medulloblastoma Study

Phase 2

Not yet recruiting

Conditions: Medulloblastoma
Medulloblastoma, Non-WNT/Non-SHH

Interventions: Drug: Digoxin

First Posted Date: 2024-11-22

Last Posted Date: 2024-12-19

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 23

Registration Number: NCT06701812

Locations: 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸
UT Southwestern, Dallas, Texas, United States

and more 11 locations

Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

Phase 1

Recruiting

Conditions: Breast Cancer Metastatic Breast Cancer
HER2-negative Breast Cancer

Interventions: Drug: Elacestrant
Biological: DC1 native/mutated ESR1

First Posted Date: 2024-11-15

Last Posted Date: 2024-11-21

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 18

Registration Number: NCT06691035

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

Phase 2

Recruiting

Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML)

Interventions: Drug: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen
Drug: Venetoclax

First Posted Date: 2024-10-28

Last Posted Date: 2024-12-19

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 52

Registration Number: NCT06660368

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

Phase 2

Recruiting

Conditions: Chronic Graft-versus-host Disease (cGVHD)

Interventions: Drug: Ruxolitinib
Drug: Prednisone

First Posted Date: 2024-10-28

Last Posted Date: 2024-12-27

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 120

Registration Number: NCT06660355

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy